This seminar will introduce GenoBioTX’s gene editing platform and technology, highlighting how these techniques can enhance your research projects. We will cover the history of genome editing, provide an overview of GenoBioTX’s gene editing platform and technology, and present case studies that demonstrate how our gene editing techniques can facilitate research advancements.
The 2024 Nobel Prize in Physiology or Medicine awarded to Victor Ambros and Gary Ruvkun for their discovery of microRNA (miRNA) highlights its revolutionary role in gene regulation and disease treatment. This article explores miRNA's impact on neuroscience, cancer, and cardiovascular research. GenoBioTX offers advanced microRNA mouse models and customized genetic solutions, empowering researchers with essential tools to drive innovation in miRNA studies and therapeutic developments.
Join us for an insightful webinar discussing advanced methodologies for generating monoclonal antibodies. This session will cover traditional and innovative approaches, highlighting their advantages and challenges.
We are excited to announce that GenoBioTX has launched a new service featuring mouse bone metastasis cancer models and pain-related behavior assessment, designed to support cancer research and pain management effectively.
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Shanghai Model Organisms Center Inc.(SMOC) received the approval of Animal Welfare Assurance from the Office of Laboratory Animal Welfare (OLAW) of the U.S. National Institutes of Health (NIH) for its animal facility on January 25, 2021.
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Join us for an insightful webinar exploring the critical role of in vivo tumor models in advancing cancer drug therapy. We will provide an overview of the diverse tumor models developed by our company, highlighting case studies demonstrating their effectiveness in preclinical cancer research. The session will delve into the comprehensive use of gene-modified cell lines and genetically modified spontaneous mouse models, showcasing their application in mimicking human cancer biology. We will conclude with a brief introduction to our company and our commitment to accelerating cancer drug development through innovative animal modeling services.
Join GenoBioTX's webinar on July 25th to explore the latest advancements in humanized mouse models for preclinical research. Learn how these models are transforming targeted therapy development across various diseases. Featuring expert insights from Dr. Derek Reznik, discover the generation and application of humanized immune system models in oncology drug development. Don't miss this opportunity to enhance your knowledge in cutting-edge preclinical therapeutic advancements. Register now!
Join us for a webinar on June 26th, 2024, exploring the development and preclinical evaluation of Antibody-Drug Conjugates (ADCs). Learn from Dr. Hua Wei, VP of the Industrial Clients Department at GenoBioTX, about ADC components, mechanisms, historical evolution, and future directions.
